Managed Access Program (MAP) to provide access to CTL019 for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: acute lymphoblastic leukemia
  • Age: Between 0 - 99 Years
  • Gender: Male or Female

Recruitment Status

Enrolling By Invitation

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com